Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type

Journal of Psychiatric Research

Volumn 31, Issue 6, 1997, Pages 645-655

  Maurer, K ^a   Ihl, R ^b   Dierks, T ^a   Frölich, Lutz ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Psychiatrische Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GINKGO BILOBA EXTRACT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROPHYSIOLOGY; FEMALE; GINKGO BILOBA; HUMAN; MALE; MEMORY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL;

EID: 0030775196     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(97)00022-8     Document Type: Article

References (44)

1. American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders (3rd edn. rev.) DSM-III-R. Washington DC: American Psychiatric Association.
2. Barth, S. A., Inselmann, G., Engemann, R., & Heidemann, H. T. (1991) Influences of Ginkgo biloba on cyclosporin A induced lipid peroxidation in human liver microsomes in comparison to vitamin E, glutathione and N-acetylcysteine. Biochemical Pharmacology, 41, 1521-1526.
3. Behl, C., Davis, J. B., Lesley, R., & Schubert, D. (1994). Hydrogen peroxide mediates amyloid β protein toxicity. Cell, 77, 817-827.
4. Blass, J. P. (1993). Pathophysiology of the Alzheimer's syndrome. Neurology, 43(4), S25-S38.
5. CIPS (Collegium Internationale Psychiatriae Scalarum) (1986). Internationale Skalen für Psychiatrie. Weinheim: Beltz-Test.
6. Davis, K. L., & Haroutunian, V. (1993). Strategies for the treatment of Alzheimer's disease. Neurology, 43(4), S52-S55.
7. Dieli, G., La Mantia, V., Saetta, M. & Costanzo, E. (1981). Essai clinique à double insu dans l'insuffisance cérébrale chronique. Il Lavoro Neuro Psichiatrico, 68, fasc.1/2.
8. Dierks, T., Perisic, I., Frölich, L., & Ihl, R., Maurer, K (1991). Topography of the quantitative EEG in dementia of the Alzheimer type: Relation to severity of dementia. Psychiatry Research: Neuroimaging, 40, 181-194.
9. Dorman, D. C., Côté, L. M., & Buck, W. B. (1992). Effects of an extract of Ginkgo biloba on bromethalin induced cerebral lipid peroxidation and edema in rats. American Journal of Veterinary Research, 53, 138-142.
10. Dumont, E., Petit, E., Tarrade, T., & Nouvelot, A. (1992) UV-C irradiation-induced peroxidative degradation of microsomal fatty acids and proteins: protection by an extract of Ginkgo biloba (EGb 761). Free Radical Biology and Medicine, 13, 197-203.
11. Eckmann, F., & Schlag, H. (1982). Kontrollierte doppelblindstudie zum wirksamkeitsnachweis von tebonin forte bei patienten mit zerebrovaskulärer insuffizienz. Fortschritte der Medizin, 100, 1474-1478.
12. Erzigkeit, H. (1986). Der Syndrom-kurz-test zur Erfassung Von Aufmerksamkeits-und Gedächtnisstörungen. Vaterstetten: Vless-Verlagsgesellschaft.
13. Frölich, L., & Riederer, P. (1995). Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Arzneimittelforschung/Drug Research, 45, 443-446.
14. Gräßel, E. (1992) Einfluß von Ginkgo-biloba Extrakt auf die geistige leistungsfähigkeit. Doppelblindstudie unter computerisierten meßbedingungen bei patienten mit zerebralinsuffizienz. Fortschritte der Medizin, 110, 73-76.
15. Haase, J., Halama, P., & Hörr, R. (1996) Wirksamkeit kurzdauernder infusionsbehandlungen mit Ginkgo-biloba spezialextrakt EGb 761 bei demenz vom vaskulären und Alzheimer typ. Zeitschrift für Gerontologie und Geriatrie, 29, 302-309.
16. Hachinski, V. C., Iliff, L. D., Chiak, E., du Boulay, G. H., Mc Allister, V. L., Marshall, J., Rusell, R. W., & Symon, L. (1975). Cerebral blood flow in dementia. Archives of Neurology, 32, 632-637.
17. Halama, P., Bartsch, G., & Meng, G. (1988). Hirnleistungsstörungen vaskulärer genese. Randomisierte doppelblindstudie zur wirksamkeit von Ginkgo-biloba-extrakt. Fortschritte der Medizin, 106, 408-412.
18. Hofferberth, B. (1994). The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type. A double-blind, placebo-controlled study on different levels of investigation. Human Psychopharmacology, 9, 215-222.
19. Ihl, R. & Frölich, L. (1991). Die Reisberg-Skalen, GDS, BCRS, FAST. Weinheim: Beltz-Test.
20. Ihl, R., Frölich, L., Dierks, T., Martin, E. M., & Maurer, K. (1992). Differential validity of psychometric tests in dementia of the Alzheimer type. Psychiatry Research, 44, 93-106.
21. Ihl, R. & Weyer, G. (1993). Die Alzheimer's Disease Assessment Scale (ADAS). Weinheim: Beltz-Test.
22. Kanowski, S., Herrmann, W. M., Stephan, K., Wierich, W., & Hörr, R. (1996) Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multiinfarct dementia. Pharmacopsychiatry, 29, 47-56.
23. Kanowski, S., Ladurner, G., Maurer, K., Oswald, W. D., & Stein, U. (1990). Empfehlungen zur evaluierung der wirksamkeit von nootropika. Zeitschrift für Gerontopsychologie und-Psychiatrie, 3, 67-79.
24. Karcher, L., Zagermann, P., & Krieglstein, J. (1984). Effect of an extract of Ginkgo biloba on rat brain energy metabolism in hypoxia. Naunyn-Schmiedebergs Archives of Pharmacology, 327, 31-35.
25. Kim, Y. S., Nibbelink, D. W., & Overall, J. E. (1993). Factor structure and scoring of the SKT test battery. Journal of Clinical Psychology, 49, 61-71.
26. Knapp, M. J., Knopman, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S., & Gracon, S. I. (1994). A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. Journal of the American Medical Association, 271, 985-991.
27. Krištofiková, Z., Benešová, O., & Tejkalová, H. (1992). Changes of high-affinity choline uptake in the hippocampus of old rats after long-term administration of two nootropic drugs (tacrine and Ginkgo biloba extract). Dementia, 3, 304-307.
28. Lehrl, S. (1977). Manual zum MWT-B. Erlangen: Perimed.
29. Le Poncin Lafitte, M., Rapin, J., & Rapin, J. R. (1980). Effects of Ginkgo biloba on changes induced by quantitative cerebral microembolization in rats. Archives Internationales de Pharmacodynamie, 243, 236-244.
30. Leroy, M., Salaün, P., Chovelon, R. & Bouilloux, E. (1978). Approche clinique et psychométrique en gériatrie. Méthodes d'études et choix d'une thérapeutique. Vie Médicale, 3.
31. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology, 34, 939-944.
32. Menges, K. (1992). Proof of efficacy of nootropics for the indication "dementia" (Phase III) - Recommendations. Pharmacopsychiatry, 25, 126-135.
33. Moreau, P. H. (1975). Un nouveau stimulant circulatoire cérébral. La Nouvelle Presse Médicale, 4, 2401-2402.
34. Noether, G. E. (1987). Sample size determination for some common nonparametric tests. Journal of the American Statistical Association, 82, 645-647.
35. Oswald, W. D. & Roth, E. (1978). Der Zahlen-Verbindungs-Test (ZVT). Göttingen: Hogrefe..
36. Parker, W. D., & Parks, J. K. (1995). Cytochrome C oxidase in Alzheimer's disease brain: Purification and characterization. Neurology, 45, 482-486.
37. Pincemail, J., Dupuis, M., Nasr, C., Hans, P., Haag-Berrurier, M., Anton, R., & Deby, C. (1989). Superoxide anion scavenging effect and superoxide dismutase activity of Ginkgo biloba extract. Experientia, 45, 708-712.
38. Prehn, J. H. M., Bindikas, V. P., Jordán, J., Galindo, M. F., Ghadge, G. D., Roos, R. P., Boise, L. H., Thompson, C. B., Krajewski, S., Reed, J. C., & Miller, R. J. (1996). Protective effect of transforming growth factor-β1 on β-amyloid neurotoxicity in rat hippocampal neurons. Molecular Pharmacology, 49, 1-10.
39. Reisberg, B., & Ferris, S. H. (1988). Brief Cognitive Rating Scale (BCRS). Psychopharmacology Bulletin, 24, 629-636.
40. Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141, 1356-1364.
41. Spinnewyn, B., Blavet, N., & Clostre, F. (1986). Effets de l'extrait de Ginkgo biloba sur un modèle d'ischémie cérébrale chez la gerbille. La Presse Médicale, 15, 1511-1515.
42. Taylor, J. E. (1985). In A. Agnoli, J. R. Rapin, V. Scapagnini & W. U. Weitbrecht (Eds). Effects of Ginkgo biloba Extract on Organic Cerebral Impairment. London: Libbey.
43. Weiß, H., & Kallischnigg, G. (1991) Ginkgo biloba extrakt (EGb 761). Metaanalyse von studien zum nachweis der therapeutischen wirksamkeit bei hirnleistungsstörungen bzw. Peripherer arterieller Verschlußkrankheit. Münchner Medizinische Wochenschrift, 133, 138-142.
44. Weitbrecht, W.-U., & Jansen, W. (1986). Primär degenerative demenz: Therapie mit Ginkgo-biloba extrakt. Placebokontrollierte doppelblind-und vergleichsstudie. Fortschritte der Medizin, 104, 199-202.